Erectile Dysfunction

True, the drug enhanced engorgement of vaginal tissue, just as it had of the penis, but that extra bit of pelvic swelling did nothing to amplify women's Advertisementdesire for or enjoyment of sex.

What is needed for the treatment of so-called female hypoactive sexual desire disorder, researchers decided, is a reasonably safe and effective drug that acts on the central nervous system, on the pleasure centers of the brain or the sensory circuitry that serves them.

For a while, many sex therapists and doctors were optimistic about Procter & Gamble's Intrinsa, a testosterone patch that delivers small transdermal pulses of the sex hormone thought to play a crucial if poorly understood role in male and female libido alike.

But in 2005, the Food and Drug Administration refused to approve Intrinsa, declaring that its medical risks outweighed whatever modest and spotty benefits it might offer.

More recently, another potentially promising treatment for hypoactive desire has been making its way through clinical trials.

The compound, called bremelanotide, is a synthetic version of a hormone involved in skin pigmentation, and it was initially developed by Palatin Technologies of New Jersey as a potential tanning agent to help prevent skin cancer.

But when male college students participating in early safety tests began reporting that the drug sometimes gave them erections, the company bega...

In addition, Senetek has entered into exclusive licenses for Europe and North America, respectively, for its patented combination drug treatment for Visit Senetek PLC's Web site at http://www.senetekplc.com.

Safe Harbor Statement: This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act, including those indicating the financial outlook for fiscal 2007 and those that might imply commercial potential and successful evaluation and development of new compounds.

Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements.

Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2006.

Howeve...

Related Topics case studies pearls of wisdom search engine marketing multi-channel marketing ad buying & planning branding media convergence seniors healthcare ad targeting Search email this story « Related stories: Merck Shifts More Advertising to Online Older Adults Using Internet More, Traditional Media Less Drug Company Runs Yahoo AIDS Day Campaign Study: Internet Important to Purchase Decision Subscribe to MarketingVOX Privacy Policy...